Maco-B Biopharma Climbs 5% On Second Trading Day
Maco-B Biopharma (2335.HK) climbed more than 5% during Hong Kong trading to HKD38.86.
The stock debuted yesterday at the HKD18.2 IPO price, closing up approximately 103% to HKD36.9. Today marks the second trading day as prices continued higher, touching a new listing high of HKD39.42 intraday.
As the first northwest China innovative drug company listed under Rule 18A, the firm focuses on peptide therapeutics with its core product MT1013 in Phase III clinical trials. The IPO public offering was oversubscribed by approximately 1,181 times, with pre-market trading previously gaining over 95%.
Source: HK Stock Market Update The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments